These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 29222275)

  • 1. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.
    Gaidano G; Rossi D
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):329-337. PubMed ID: 29222275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    Brown JR; Hallek MJ; Pagel JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    Suzumiya J; Takizawa J
    Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic lymphatic leukemia].
    Bergmann M; Wendtner CM
    Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How should we sequence and combine novel therapies in CLL?
    Davids MS
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
    Edelmann J; Gribben JG
    J Oncol Pract; 2017 Jun; 13(6):371-377. PubMed ID: 28605616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
    Pospisilova S; Sutton LA; Malcikova J; Tausch E; Rossi D; Montserrat E; Moreno C; Stamatopoulos K; Gaidano G; Rosenquist R; Ghia P;
    Haematologica; 2016 Mar; 101(3):263-5. PubMed ID: 26928246
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphocytic leukaemia.
    Hallek M; Shanafelt TD; Eichhorst B
    Lancet; 2018 Apr; 391(10129):1524-1537. PubMed ID: 29477250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
    Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
    J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting Frontline Therapy for CLL in 2018.
    Jain N
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):242-247. PubMed ID: 30504317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Shustik C; Bence-Bruckler I; Delage R; Owen CJ; Toze CL; Coutre S
    Ann Hematol; 2017 Jul; 96(7):1185-1196. PubMed ID: 28389687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
    Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
    Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal dynamics in chronic lymphocytic leukemia.
    Gutierrez C; Wu CJ
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):466-475. PubMed ID: 31808879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
    García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F;
    Med Clin (Barc); 2017 Apr; 148(8):381.e1-381.e9. PubMed ID: 28236475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
    Cramer P; Langerbeins P; Eichhorst B; Hallek M
    Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
    Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
    Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.